Shots:

• The company initiates a P-III MOVe-AHEAD trial to evaluate molnupiravir (800 mg- q12h for 5 days) vs PBO in ~1-332 participants aged 18yrs. who reside in the same household as someone with laboratory-confirmed SARS-CoV-2 infection with symptoms. The trial is being conducted globally
• The 1EPs of trial i.e.- proportion of participants with COVID-19 (laboratory-confirmed) @14days- percentage of participants with an AEs & who discontinued the study due to AEs
• The safety & efficacy of molnupiravir is also being evaluated in Part 2 of an ongoing P-III MOVe-OUT trial for non-hospitalized patients with at least one risk factor due to poor disease outcomes. The results are expected in H2’21

Ref: Businesswire | Image: Merck